11.10.26 -- What's Next For Oligo Manufacturing?

Oligonucleotide therapeutics are revolutionizing the way scientists target molecules that are beyond the reach of conventional drugs. To meet demand, manufacturing must shift to larger-scale processes, but scaling up brings challenges that must be addressed.

The separation of cleavage, deprotection, and tangential flow filtration in oligonucleotide production may be more historical than fundamental. Hear about what made combining them feasible, where the hardest design trade-offs arose, and how customer input shaped the result.

Oligonucleotide therapeutics target disease at the RNA level, but scaling synthesis without sacrificing quality is difficult. Raw material costs, limited funding, and skill shortages create bottlenecks, while solid-phase and liquid-phase methods each carry distinct trade-offs for manufacturers.

Scaling oligonucleotide synthesis isn't as straightforward as it seems. Examine its challenges and how they can be addressed through innovative automation, intuitive software, and expert support for smoother transitions and optimized processes.

Scaling oligonucleotide manufacturing means choosing equipment for each stage of the process, not just the synthesizer. Automation, scalability, quality monitoring, total cost of ownership, and vendor support all affect how well a facility adapts as production needs change.

Learn about high-performance and scalable THESYS OS oligosynthesizers, which feature advanced process controls and automation for efficient and reliable oligonucleotide synthesis.